The US Food and Drug Administration has approved a change in the dosage of Faslodex® to 500 mg; previously, the approved dose was 250 mg. Faslodex is used for treatment of metastatic breast cancer following progression of disease in estrogen receptor-positive post-menopausal women who had previously received antiestrogen treatment. US FDA approval for the increase is based on the results that show a reduced risk of disease progression and also an increase in survival.
5 6 7 8
© 2004-2010 Donna Peach. All rights reserved.